These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 10336525)

  • 1. BIIR 561 CL: a novel combined antagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors and voltage-dependent sodium channels with anticonvulsive and neuroprotective properties.
    Weiser T; Brenner M; Palluk R; Bechtel WD; Ceci A; Brambilla A; Ensinger HA; Sagrada A; Wienrich M
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1343-9. PubMed ID: 10336525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo pharmacology of BIIR 561 CL, a novel combined antagonist of AMPA receptors and voltage-dependent Na(+) channels.
    Wienrich M; Brenner M; Löscher W; Palluk R; Pieper M; Potschka H; Weiser T
    Br J Pharmacol; 2001 Jul; 133(6):789-96. PubMed ID: 11454651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity.
    Nielsen EO; Varming T; Mathiesen C; Jensen LH; Moller A; Gouliaev AH; Wätjen F; Drejer J
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1492-501. PubMed ID: 10336544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the anticonvulsant and neuroprotectant BIIR 561 CL in vitro: effects on native and recombinant alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors.
    Weiser T; Iizuka M; Nishimura S; Akiba I; Barsoumian E; Zhou M; Steinhäuser C; Brenner M; Palluk R; Wienrich M
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Nov; 362(4-5):419-26. PubMed ID: 11111837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent blockade of sodium channels and protection of brain tissue from ischemia by BIII 890 CL.
    Carter AJ; Grauert M; Pschorn U; Bechtel WD; Bartmann-Lindholm C; Qu Y; Scheuer T; Catterall WA; Weiser T
    Proc Natl Acad Sci U S A; 2000 Apr; 97(9):4944-9. PubMed ID: 10781102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo.
    Gasparini F; Bruno V; Battaglia G; Lukic S; Leonhardt T; Inderbitzin W; Laurie D; Sommer B; Varney MA; Hess SD; Johnson EC; Kuhn R; Urwyler S; Sauer D; Portet C; Schmutz M; Nicoletti F; Flor PJ
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1678-87. PubMed ID: 10336568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The AMPA receptor/Na(+) channel blocker BIIR 561 CL is protective in a model of global cerebral ischaemia.
    Weiser T; Wienrich M; Brenner M; Kubiak R; Weckesser G; Palluk R
    Eur J Pharmacol; 2001 Jun; 421(3):165-70. PubMed ID: 11516432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity.
    Donevan SD; Yamaguchi S; Rogawski MA
    J Pharmacol Exp Ther; 1994 Oct; 271(1):25-9. PubMed ID: 7525924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RPR 119990, a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis.
    Canton T; Böhme GA; Boireau A; Bordier F; Mignani S; Jimonet P; Jahn G; Alavijeh M; Stygall J; Roberts S; Brealey C; Vuilhorgne M; Debono MW; Le Guern S; Laville M; Briet D; Roux M; Stutzmann JM; Pratt J
    J Pharmacol Exp Ther; 2001 Oct; 299(1):314-22. PubMed ID: 11561094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nefopam blocks voltage-sensitive sodium channels and modulates glutamatergic transmission in rodents.
    Verleye M; André N; Heulard I; Gillardin JM
    Brain Res; 2004 Jul; 1013(2):249-55. PubMed ID: 15193535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor antagonists of 2,3-benzodiazepine type: chemical synthesis, in vitro characterization, and in vivo prevention of acute neurodegeneration.
    Elger B; Huth A; Neuhaus R; Ottow E; Schneider H; Seilheimer B; Turski L
    J Med Chem; 2005 Jul; 48(14):4618-27. PubMed ID: 15999999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective activity of stiripentol with a possible involvement of voltage-dependent calcium and sodium channels.
    Verleye M; Buttigieg D; Steinschneider R
    J Neurosci Res; 2016 Feb; 94(2):179-89. PubMed ID: 26511438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium channel blocking activity of AM-36 and sipatrigine (BW619C89): in vitro and in vivo evidence.
    Callaway JK; Castillo-Melendez M; Giardina SF; Krstew EK; Beart PM; Jarrott B
    Neuropharmacology; 2004 Jul; 47(1):146-55. PubMed ID: 15165842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator.
    Baumbarger PJ; Muhlhauser M; Zhai J; Yang CR; Nisenbaum ES
    J Pharmacol Exp Ther; 2001 Jul; 298(1):86-102. PubMed ID: 11408529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kynurenic acid analogues with improved affinity and selectivity for the glycine site on the N-methyl-D-aspartate receptor from rat brain.
    Foster AC; Kemp JA; Leeson PD; Grimwood S; Donald AE; Marshall GR; Priestley T; Smith JD; Carling RW
    Mol Pharmacol; 1992 May; 41(5):914-22. PubMed ID: 1375317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
    Shimizu-Sasamata M; Kawasaki-Yatsugi S; Okada M; Sakamoto S; Yatsugi S; Togami J; Hatanaka K; Ohmori J; Koshiya K; Usuda S; Murase K
    J Pharmacol Exp Ther; 1996 Jan; 276(1):84-92. PubMed ID: 8558460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization.
    Parsons CG; Danysz W; Quack G; Hartmann S; Lorenz B; Wollenburg C; Baran L; Przegalinski E; Kostowski W; Krzascik P; Chizh B; Headley PM
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1264-75. PubMed ID: 9400002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological properties of trimebutine and N-monodesmethyltrimebutine.
    Roman FJ; Lanet S; Hamon J; Brunelle G; Maurin A; Champeroux P; Richard S; Alessandri N; Gola M
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1391-7. PubMed ID: 10336531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new 2,3-benzodiazepine derivative EGIS-8332 inhibits AMPA/kainate ion channels and cell death.
    Vegh MG; Kovács AD; Kovács G; Szabó G; Tihanyi K; Hársing LG; Lévay G
    Neurochem Int; 2007 Feb; 50(3):555-63. PubMed ID: 17147974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.
    Murray TK; Whalley K; Robinson CS; Ward MA; Hicks CA; Lodge D; Vandergriff JL; Baumbarger P; Siuda E; Gates M; Ogden AM; Skolnick P; Zimmerman DM; Nisenbaum ES; Bleakman D; O'Neill MJ
    J Pharmacol Exp Ther; 2003 Aug; 306(2):752-62. PubMed ID: 12730350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.